

## **IMS FORM**

B. Braun UK Companies - Board Statement on The Bribery Act 2010 B. Braun Medical UK Ltd

IMS UK

Doc-No.: SA-GB02-G-4-3-02-001-01-A-EN

Version: 3.0

Effective date: 17.05.2023

## Dear Colleagues,

The Bribery Act became effective on 1st July 2011 and applies to all of us, at all levels, within each business area and function of our organisation. We would like to communicate the following policy to you:

- 1. As a UK and International organisation B. Braun is committed to carrying out its business fairly, honestly and openly.
- 2. We believe that conducting business in this way ensures we maintain a strong reputation in all the markets where we operate and creates sustainable business relationships with customers, suppliers and other business partners alike.
- 3. We will not tolerate bribery of any type, at any level, or for any purpose, within our business.
- 4. We will not conduct business with customers, suppliers or other third parties who do not also conduct their business in compliance with the Bribery Act.
- 5. Our internal policies and procedures govern how we will conduct our business in order to uphold these standards of fairness, honesty and openness and to avoid breaching the Bribery Act. These policies and procedures are set out in the Information Management System (IMS), in the B. Braun Knowledge Centre (BKC), and can be obtained from your line managers.
- 6. We will continually review, update and add to our policies and procedures to ensure that we can all remain compliant with the requirements of the Bribery Act.
- 7. It is your duty to ensure you are familiar with the terms of the Bribery Act and B. Braun's policies and procedures. Failure to adhere to them may result in disciplinary action and could amount to a breach of the Bribery Act on your part.
- 8. We will fully support and assist you in understanding the Bribery Act, your duties and B. Braun's policies and procedures.
- 9. We will also support you in identifying, avoiding and, if necessary, reporting behavior which breaches B. Braun's policies and procedures, and which may amount to bribery under the terms of the Bribery Act.
- 10. Your line managers and the Executive Committee members are available to answer any questions or concerns you may have concerning the Bribery Act, our policies and procedures, and any specific business issues which may arise.

Michael Parden
Managing Director

Paul Skelton
Managing Director, Finance
I.T & Operations

HA

Donna Gold

Director, B. Braun Medical Ltd., In House Legal Counsel and Compliance Officer